48,384 results match your criteria Journal of Crohn's & colitis[Journal]


Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 19. Epub 2019 Feb 19.

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Background: Patients with Crohn's disease (CD) responding to anti-tumor necrosis factor (anti-TNF) show great variability in serum drug levels, even within the therapeutic range. We aimed at exploring the role of inflammatory, genetic, and bacterial variables in relation to anti-TNF through levels in CD patients.

Methods: Consecutive CD patients receiving stable doses of infliximab or adalimumab were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz012DOI Listing
February 2019

Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.

Medchemcomm 2019 Jan 20;10(1):169-179. Epub 2018 Dec 20.

Department of Chemistry , Kansas State University , 1212 Mid-Campus Drive North , Manhattan , KS 66506 , USA . Email:

6-Thiopurine (6TP) is a currently prescribed drug in the treatment of diseases ranging from Crohn's disease to acute lymphocytic leukemia. While its potent mode of action is through incorporation into DNA as a thiol mimic of deoxyguanosine, severe toxicities are associated with its administration which hinder the potential therapeutic application. We have previously reported that the oxidative metabolites of 6TP, specifically 6-thiouric acid (6TU, 7 μM), are potent inhibitors of UDP-glucose dehydrogenase (UDPGDH), an enzyme that is responsible for the formation of UDP-glucuronic acid (UDPGA), an essential substrate that is used in detoxification processes in the liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8md00463cDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350761PMC
January 2019

Effect of Irritable Bowel Syndrome on Sleep Quality and Quality of Life of Inflammatory Bowel Disease in Clinical Remission.

Int J Prev Med 2019 15;10:10. Epub 2019 Jan 15.

Department of Internal Medicine, Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Background: Inflammatory bowel disease (IBD) as a chronic and debilitating disease is affected by sleep disturbance which increases the risk of malignancy. Sleep disturbance is more common in irritable bowel syndrome (IBS) and few reported studies have assessed its role in IBD. We evaluated the effect of IBS on sleep quality and quality of life (QOL) of IBD patients in clinical remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijpvm.IJPVM_364_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360848PMC
January 2019

Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S124-S128

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Here, we evaluated the role of (iNOS) as a blood-based biomarker of inflammatory bowel diseases (IBD).

Background: Up-regulation of inducible nitric oxide synthase (iNOS) in the intestinal epithelial cells has been closely associated with the initiation and maintenance of intestinal inflammation in IBD.

Methods: In a case-control design, 59 IBD patients and 30 healthy control subjects were participated in this study. Read More

View Article

Download full-text PDF

Source
January 2018

Evaluation of IL-12A, IL-12B, IL-23A and IL-27 mRNA expression level genes in peripheral mononuclear cells of inflammatory bowel disease patients in an Iranian population.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S45-S52

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Aim of this study was to compare the gene expression of Interleukin 12 members in two phase of IBD.

Background: Inflammatory bowel disease (IBD) is a well-known gastrointestinal disorder in the world that fluctuates between remission and flare-up phases. Each of these phases has an individual immune system response profile. Read More

View Article

Download full-text PDF

Source
January 2018

Determining the degree of adherence to treatment in inflammatory bowel disease patients.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S39-S44

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Since the inflammatory bowel disease (IBD) is a disorder which requires continuous drug intake to induce and maintain the remission phase, finding the barriers for low adherent group, may improve the disease phase and quality of life in those patients.

Background: IBD is defined as a chronic immune disorder with unpredictable flares. The common treatment of these diseases can be effective for inducing and maintaining remission courses. Read More

View Article

Download full-text PDF

Source
January 2018

subsp. induces differential cytosine methylation at miR-21 transcription start site region.

Iran J Vet Res 2018 ;19(4):262-269

Department of Basic Sciences, and Division of Biotechnology, Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.

subspecies s (MAP), as an obligate intracellular bacterium, causes (Johne's disease) in ruminants. Plus, MAP has consistently been isolated from Crohn's disease (CD) lesions in humans; a notion implying possible direct causative effect for MAP in CD development. Infections caused by MAP are refractory to treatment and in many cases the treatment does not easily resolve the infection. Read More

View Article

Download full-text PDF

Source
January 2018

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease.

Front Pharmacol 2019 1;10:39. Epub 2019 Feb 1.

Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Kussmaul Campus for Medical Research and Translational Research Center, Erlangen, Germany.

Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in several phase III trials. Mechanistically, etrolizumab is known to block β7 integrin ligand binding and reduces intestinal trafficking of β7-expressing cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367223PMC
February 2019

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome.

Clin Exp Gastroenterol 2019 31;12:37-49. Epub 2019 Jan 31.

Department of Pediatrics, Oslo University Hospital, Ullevål, Oslo, Norway.

Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes.

Patients And Methods: Fecal samples were collected from 235 children below 18 years of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEG.S186235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362922PMC
January 2019

Fatigue in children and adolescents with inflammatory bowel disease.

World J Gastroenterol 2019 Feb;25(5):632-643

Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Aim: To identify factors other than active disease and anemia that contribute to fatigue in pediatric inflammatory bowel disease (IBD).

Methods: We performed an electronic search in Medline and EMBASE from their inception to May 2017 using the search term "fatigue" or the related keywords "physical impairment" and "inflammatory bowel disease" with the filter "child" (age 0-18 years). Cross-sectional and case-control studies were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i5.632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371006PMC
February 2019

The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice.

Innate Immun 2019 Feb;25(2):132-143

1 Merck Research Laboratories, Boston, MA, USA.

Crohn's disease (CD) is a chronic disorder of the gastrointestinal tract characterized by inflammation and intestinal epithelial injury. Loss of function mutations in the intracellular bacterial sensor NOD2 are major risk factors for the development of CD. In the absence of robust bacterial recognition by NOD2 an inflammatory cascade is initiated through alternative PRRs leading to CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753425919826367DOI Listing
February 2019
1 Read

[Herbal cake-partitioned moxibustion improves intestinal epithelial barrier dysfunction by suppressing TNF-α-mediated apoptosis pathway of intestinal epithelium in rats with Crohn's disease].

Zhen Ci Yan Jiu 2019 Jan;44(1):1-7

Yueyang Clinical Medical School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Shanghai Research Institute of Acupuncture-moxibustion and Meridian, Shanghai 200030.

Objective: To observe the effect of herbal cake-partitioned moxibustion (Moxi) on tumor necrosis factor (TNF)-α/ TNF receptor 1 (TNFR1)-associated death domain (TRADD) / Fas-associated death domain (FADD) pathway-mediated apoptosis of intestinal epithelial cells in Crohn's disease (CD) rats, so as to explore its underlying mechanisms in the treatment of CD.

Methods: Forty-eight SD male rats were randomly divided into normal, model, Moxi and medication groups (=12 rats in each). The CD model was established by intra-annual perfusion of 2,4,6-trinitrobenzene sulfonic acid (TNBS) solution (TNBS∶50% alcohol=2∶1, 3 mL/kg), once every 7 days, 4 times altogether. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13702/j.1000-0607.180512DOI Listing
January 2019

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Background: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population.

Aim: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age.

Methods: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15177DOI Listing
February 2019

Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York.

Background: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations.

Aim: Our primary aim was to identify whether sex-based differences in IBD incidence similarly exist across the age spectrum for Asia-Pacific populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15178DOI Listing
February 2019

Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.

J Pediatr Surg 2019 Jan 18. Epub 2019 Jan 18.

Division of Pediatric Surgery, Mayo Clinic, Rochester, MN, USA.

Introduction: Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation.

Methods: A retrospective chart review was performed on pediatric (<18 years of age) CD patients who underwent an abdominal operation between 1/1/2008 and 12/31/2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpedsurg.2019.01.006DOI Listing
January 2019

Successful EUS-guided Drainage of a Persistent Subdiaphragmatic Fluid Collection in a Patient With Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 15. Epub 2019 Feb 15.

From the Gastroenterology and Hepatology Department, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz018DOI Listing
February 2019

Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.

Inflamm Bowel Dis 2019 Feb 17. Epub 2019 Feb 17.

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Background: Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites between newly diagnosed and untreated pediatric patients with Crohn's disease (CD) or ulcerative colitis (UC) in comparison with a control group (Ctr). Moreover, we investigated the potential of profiling metabolomics and inflammatory markers to improve the noninvasive diagnosis of CD and UC in children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy402DOI Listing
February 2019

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease.

Clin Gastroenterol Hepatol 2019 Feb 14. Epub 2019 Feb 14.

Gastrointestinal Unit, Western General Hospital, Edinburgh, UK; University of Edinburgh, UK.

Background & Aims: Mucosal healing is associated with improved outcomes in patients with Crohn's disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease activity in place of endoscopy-this measurement is an important component of the treat to target strategy. We investigated whether levels of fecal calprotectin associate with subsequent CD progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.02.017DOI Listing
February 2019
5 Reads

Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease.

Gastroenterology 2019 Feb 14. Epub 2019 Feb 14.

Department of Surgery, Pelvic Floor Unit, Aarhus University Hospital, Aarhus, Denmark.

Background And Aims: Perianal fistulas are common in patients with Crohn´s disease (CD). Injections of cultured autologous and allogeneic adipose tissue-derived stem cells have been shown to heal CD-associated fistulas. Unfortunately, this treatment is time-consuming and expensive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.02.005DOI Listing
February 2019

Acute abdominal pain in patients with Crohn's disease: what urgent imaging tests should be done?

Radiologia 2019 Feb 13. Epub 2019 Feb 13.

Servicio de Radiología, Hospital Universitario Ramón y Cajal, Madrid, España.

Crohn's disease is an autoimmune disease that predominantly affects the gastrointestinal tract. Crohn's disease is diagnosed at a young age and runs a chronic course with acute flare-ups. When patients with Crohn's disease present with flare-ups at the emergency department, they are usually managed in a way similar to patients with acute abdomen; there is no consensus about the most appropriate imaging work-up for patients with flare-ups of Crohn's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rx.2018.12.003DOI Listing
February 2019

Thrombotic complications in inflammatory bowel diseases.

G Chir 2019 Jan-Feb;40(1):14-19

Inflammatory bowel disease (IBD), Crohn's Disease (CD) and Ulcerative Colitis (UC) are associated with an increased risk of arterial and venous thromboembolism. A 2 to 3 time fold increased risk of developing thromboembolic complications was reported for IBD patients compared to general population. A systematic literature search was conducted using PubMed, Medline, Scopus, Cochrane database. Read More

View Article

Download full-text PDF

Source
February 2019

A Novel Rare Missense Variation of the Gene: Evidencesof Implication in Crohn's Disease.

Int J Mol Sci 2019 Feb 15;20(4). Epub 2019 Feb 15.

EA 2694-Santé Publique: épidémiologie et qualité des soins, University Lille, CHU Lille, F-59000 Lille, France.

The gene, involved in innate immune responses to bacterial peptidoglycan, has been found to be closely associated with Crohn's Disease (CD), with an Odds Ratio ranging from 3⁻36. Families with three or more CD-affected members were related to a high frequency of gene variations, such as R702W, G908R, and 1007fs, and were reported in the EPIMAD Registry. However, some rare CD multiplex families were described without identification of common linked-to-disease variations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040835DOI Listing
February 2019
1 Read

Development of Infliximab Target Concentrations during Induction in Pediatric Crohn's Disease Patients.

J Pediatr Gastroenterol Nutr 2019 Feb 12. Epub 2019 Feb 12.

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Objectives: Subtherapeutic drug concentrations contribute to both primary and secondary nonresponse to infliximab in children with Crohn's disease (CD). The aim of this study was to evaluate treatment outcomes and infliximab concentrations at infusions 2 and 3 with an objective to establish infliximab targets during induction for primary responders.

Methods: Single-center, prospective cohort of anti-TNF naïve CD patients < 22 years old starting infliximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPG.0000000000002304DOI Listing
February 2019

A Validated Score Assessing the Risk for an Intra-Abdominal Abscess in Patients with Crohn's Disease Presenting at the Emergency Department.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Institute of Gastroenterology and Liver Diseases, Department of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Background And Aims: A majority of acutely-ill Crohn's disease (CD) patients who present to Emergency Department (ED) will undergo an abdominal CT to rule out disease complications. We aimed to generate a simple non-invasive scoring model to predict the presence of an intra-abdominal abscess in CD patients in the ED.

Methods: We performed a retrospective case control study at four Israeli hospitals from January-1 st-2010 to May-30 th-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz043DOI Listing
February 2019

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Department of Gastroenterology, Raigmore Hospital, Inverness.

Introduction: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis.

Aims: To establish the real-world efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease.

Methods: Retrospective study involving six NHS health boards in Scotland between June 2015 and November 2017. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz042DOI Listing
February 2019
1 Read

Induction of autophagy in Cx3cr1 mononuclear cells limits IL-23/IL-22 axis-mediated intestinal fibrosis.

Mucosal Immunol 2019 Feb 14. Epub 2019 Feb 14.

Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, 12208, USA.

Intestinal fibrosis is an excessive proliferation of myofibroblasts and deposition of collagen, a condition frequently seen in Crohn's disease (CD). The mechanism underlying myofibroblast hyper-proliferation in CD needs to be better understood. In this report, we found that mTOR inhibitor rapamycin or mTOR deletion in CX3Cr1 mononuclear phagocytes inhibits expression of interleukin (IL)-23, accompanied by reduced intestinal production of IL-22 and ameliorated fibrosis in the TNBS-induced fibrosis mouse model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41385-019-0146-4DOI Listing
February 2019

Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model.

Sci Rep 2019 Feb 14;9(1):2030. Epub 2019 Feb 14.

Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

Intestinal epithelial barrier is affected by multiple factors, such as tumour necrosis factor-α (TNF-α). Plasma concentration of TNF-α is higher in patients with Crohn's disease (CD) than healthy controls (HC) and correlates positively with disease activity. This study aimed to determine the effect of plasma from active, inactive CD patients on intestinal barrier function and to investigate the underlying mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38322-8DOI Listing
February 2019

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial.

J Intern Med 2019 Feb 14. Epub 2019 Feb 14.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo.

Background And Objectives: The 52-week, randomized, double blind, non-inferiority, government funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) vs patients switched to CT-P13 at week 52 (switch group).

Primary Outcome: disease worsening during follow-up based on disease specific composite measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.12880DOI Listing
February 2019

Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy

Turk J Med Sci 2019 Feb 11;49(1):42-49. Epub 2019 Feb 11.

Background/aim: Differentiating intestinal Behçet’s disease (BD) from Crohn’s disease (CD) is highly challenging, as they often mimic each other in terms of clinical manifestations. Endoscopy is an important modality for distinguishing bowel lesions. The study was designed to identify clinical manifestations that are easily confused and to evaluate the efficacy of endoscopy for distinguishing intestinal BD from CD by several overlapping signs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1807-67DOI Listing
February 2019

Mucosa-associated microbiota drives pathogenic functions in IBD-derived intestinal iNKT cells.

Life Sci Alliance 2019 Feb 13;2(1). Epub 2019 Feb 13.

Department of Experimental Oncology, IEO, European Istitute of Oncology IRCCS, Milan, Italy

Inflammatory bowel disease (IBD) pathogenesis has been linked to the aberrant activation of the Gut-associated lymphoid tissues against components of the intestinal microbiota. Although the contribution of CD4 T helper cells to inflammatory processes is being increasingly acknowledged, the functional engagement of human invariant natural killer T (iNKT) cells is still poorly defined. Here, we evaluated the functional characteristics of intestinal iNKT cells during IBD pathogenesis and to exploit the role of mucosa-associated microbiota recognition in triggering iNKT cells' pro-inflammatory responses in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26508/lsa.201800229DOI Listing
February 2019

Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice.

Gut Microbes 2019 Feb 13:1-21. Epub 2019 Feb 13.

a University of British Columbia.

Inflammatory bowel disease, encompassing both ulcerative colitis and Crohn's disease, is characterized by chronic, relapsing-remitting gastrointestinal inflammation of unknown etiology. SHIP deficient mice develop fully penetrant, spontaneous ileitis at 6 weeks of age, and thus offer a tractable model of Crohn's disease-like inflammation. Since disruptions to the microbiome are implicated in the pathogenesis of Crohn's disease, we conducted a 16S rRNA gene survey of the ileum, cecum, colon, and stool contents of SHIP and SHIP mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19490976.2018.1560767DOI Listing
February 2019

The role of topical therapy for perianal fistulizing Crohn's disease: are we forgetting something?

Minerva Gastroenterol Dietol 2019 Feb 12. Epub 2019 Feb 12.

Department of Surgical Sciences, University of Turin, Turin, Italy.

Introduction: The rectal inflammation is the principal risk factor for the development of perianal fistulizing Crohn's disease. However, no topical therapy direct to rectal healing is discussed in European' guidelines. The aim of this systematic review was to evaluate the role of topical therapy in healing the rectal inflammation in Crohn's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S1121-421X.19.02565-0DOI Listing
February 2019
7 Reads

Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study.

Inflamm Bowel Dis 2018 Aug;24(9):2015-2026

Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology.

Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This study aims to identify risk factors for oral cavity (OCC) and pharyngeal carcinoma (PC) development in IBD, to compare clinical characteristics in IBD with the general population, and to assess the influence of immunosuppressive medication on survival. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/article/24/9/2015/499994
Publisher Site
http://dx.doi.org/10.1093/ibd/izy096DOI Listing
August 2018
1 Read

Permacol™ collagen paste for cryptoglandular and Crohn's anal fistula.

Tech Coloproctol 2019 Feb 13. Epub 2019 Feb 13.

Department of General and Visceral Surgery, Friedrich-Alexander-University, Krankenhausstraße 12, 91054, Erlangen, Germany.

Background: Permacol™ collagen paste, an acellular crosslinked porcine dermal collagen matrix suspension, is a new treatment option for anal fistula. Data remain limited, however, and as yet only the results of one case of Crohn's fistula treated with Permacol™ paste has been reported. The aim of this study was to assess the use of Permacol™ collagen paste in patients with cryptoglandular and Crohn's perianal fistulae. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10151-019-01932-zDOI Listing
February 2019
1 Read

ANALYSIS OF THE CLINICAL CHARACTERISTICS OF PERIANAL FISTULISING CROHN'S DISEASE IN A SINGLE CENTER.

Arq Bras Cir Dig 2019 Feb 7;32(1):e1420. Epub 2019 Feb 7.

The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Background: Clinical characteristics are keys to improve identification and treatment of Crohn´s disease (CD) so that large sample analysis is of great value.

Aim: To explore the clinical characteristics of perianal fistulising CD.

Methods: Analysis of 139 cases focused on their clinical data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0102-672020180001e1420DOI Listing
February 2019

Tumour necrosis factor signalling in health and disease.

F1000Res 2019 28;8. Epub 2019 Jan 28.

Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, UK.

The master pro-inflammatory cytokine, tumour necrosis factor (TNF), has been shown to modulate multiple signalling pathways, with wide-ranging downstream effects. TNF plays a vital role in the typical immune response through the regulation of a number of pathways encompassing an immediate inflammatory reaction with significant innate immune involvement as well as cellular activation with subsequent proliferation and programmed cell death or necrosis. As might be expected with such a broad spectrum of cellular effects and complex signalling pathways, TNF has also been implicated in a number of disease states, such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Read More

View Article

Download full-text PDF

Source
https://f1000research.com/articles/8-111/v1
Publisher Site
http://dx.doi.org/10.12688/f1000research.17023.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352924PMC
January 2019
1 Read

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Biologicals 2019 Feb 9. Epub 2019 Feb 9.

Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients treated with vedolizumab in a nationwide, retrospective, non-interventional, multi-centre chart review study. All adult patients from 27 Finnish gastroenterology centres with a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) who had at least one vedolizumab infusion since it's availability in Finland were included in the study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10451056183033
Publisher Site
http://dx.doi.org/10.1016/j.biologicals.2019.01.007DOI Listing
February 2019
1 Read

The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Departments of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Background: Many patients with Crohn's disease (CD) are treated with medications, including steroids, immunomodulators, and anti-tumor necrosis factor alpha (anti-TNF-α) agents, at the time of surgery. This study evaluated the effects of these medications on postoperative complications in CD patients.

Methods: This retrospective study analyzed patients who underwent bowel resection for CD between January 2006 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz010DOI Listing
February 2019
2 Reads
4.464 Impact Factor

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Academic Medical Center, Amsterdam, Netherlands.

Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice.

Methods: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz008DOI Listing
February 2019
2 Reads

Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Background: Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract. Surfactant protein D (SP-D) is expressed in the intestinal epithelium and is essential for innate host defense and regulation of inflammatory responses. Genetic variations of SP-D are associated with IBD, but the effects of SP-D in clinical disease development have not been clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz009DOI Listing
February 2019
1 Read

Identification of Chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn's disease.

J Crohns Colitis 2019 Feb 7. Epub 2019 Feb 7.

Institute for Biotechnology, Faculty of Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz, Senftenberg, Germany.

Objective: There is an increasing incidence of inflammatory bowel disease (IBD). Autoimmune responses partake in the pathophysiology of IBD, however, its underlying pathways and target antigens are not yet fully elucidated.

Methods: Autoantigenic targets in IBD were identified after separation of whole cell proteins isolated from neutrophils using two dimensional electrophoresis and Matrix Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometry (MALDI-TOF-MS) based protein identification of the spots that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody (ANCA)-positive sera. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz012DOI Listing
February 2019
1 Read

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).

J Crohns Colitis 2019 Feb 8. Epub 2019 Feb 8.

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Background: Combining a thiopurine with the human anti-tumor necrosis factor- monoclonal antibody adalimumab for Crohn's disease (CD) treatment is controversial with regard to efficacy and safety. By conducting a sub-analysis of a multicenter, randomized, prospective, open-label trial (the DIAMOND study, UMIN registration number 000005146), we studied the risk of discontinuation of thiopurine in combination with adalimumab.

Methods: In the preceding DIAMOND study, we analyzed the: (i) timing and reasons for dropout in the monotherapy group and combination group; (ii) risk factors for dropout in the combination group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz030DOI Listing
February 2019
2 Reads

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

J Crohns Colitis 2019 Feb 9. Epub 2019 Feb 9.

Division of Gastroenterology, Icahn School of Medicine at Mt Sinai, New York, NY, USA.

Background And Aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort.

Methods: Data were pooled from 10 clinical trials in patients with moderately to severely active CD who received treatment with either adalimumab or placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy223DOI Listing
February 2019

A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency.

Am J Gastroenterol 2019 Feb 8. Epub 2019 Feb 8.

Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Objectives: Common variable immunodeficiency (CVID) is associated with a spectrum of autoimmune complications. We studied the prevalence of gastrointestinal (GI) manifestations and infections in patients with CVID.

Methods: Complete clinical data of 132 Finnish patients with CVID (106 probable and 26 possible CVID) followed up between 2007 and 2016 were collected to a structured database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000140DOI Listing
February 2019
1 Read

Ileocolic Resection for Crohn's Disease: A Minimally Invasive Approach Claims Its Place.

Am Surg 2018 Oct;84(10):1639-1644

Department of Surgery, University of California, Irvine, School of Medicine, Irvine, California, USA.

Ileocolic resection is the most common operation performed for Crohn's disease patients with terminal ileum involvement. We sought to evaluate the outcomes in Crohn's disease patients who underwent open ileocolic resection (OIC) and laparoscopic ileocolic resection (LIC) by using the ACS-NSQIP database from 2006 to 2015. Of 5670 patients, 48. Read More

View Article

Download full-text PDF

Source
October 2018

Role of the Gut Microbiome in Autism Spectrum Disorders.

Adv Exp Med Biol 2019 ;1118:253-269

Department of Genomics, Central University of Kerala, Kasaragod, Kerala, India.

Autism spectrum disorder (ASD) is a severe neurodevelopmental or neuropsychiatric disorder with elusive etiology and obscure pathophysiology. Cognitive inabilities, impaired communication, repetitive behavior pattern, and restricted social interaction and communication lead to a debilitating situation in autism. The pattern of co-occurrence of medical comorbidities is most intriguing in autism, compared to any other neurodevelopmental disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-05542-4_13DOI Listing
January 2019
1 Read

Phenotypes in Behçet's syndrome.

Authors:
Emire Seyahi

Intern Emerg Med 2019 Feb 11. Epub 2019 Feb 11.

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, 81310, Istanbul, Turkey.

Behçet syndrome (BS) is a multi-systemic complex disorder with unknown etiology and a unique geographic distribution. It could not be possible to include it into specific classification schemes and it is certainly not a uniform disease. Several cluster and association studies revealed that it has been composed of multiple phenotypes ascribing the principal problem such as skin-mucosa, joint, eye, vascular, neurological and gastrointestinal involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-019-02046-yDOI Listing
February 2019
2 Reads

Ulcer-associated cell lineage expresses genes involved in regeneration and is hallmarked by high neutrophil gelatinase-associated lipocalin (NGAL) levels.

J Pathol 2019 Feb 11. Epub 2019 Feb 11.

Centre of Molecular Inflammation Research, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.

Neutrophil gelatinase associated lipocalin (NGAL), also known as Lipocalin 2, is an antimicrobial protein, encoded by the gene LCN2, strongly upregulated in inflammatory bowel disease (IBD) and a promising biomarker for IBD. Here we demonstrate that NGAL is highly expressed in all parts of pyloric metaplasia, also known as the ulcer-associated cell lineage (UACL), a metaplastic cell lineage suggested to play a role in wound healing in Crohn's disease (CD). We further show NGAL expression in regenerative intestinal crypts and in undifferentiated patient-derived colonoids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5258DOI Listing
February 2019

Receipt of Preventive Care Services Among US Adults with Inflammatory Bowel Disease, 2015-2016.

Dig Dis Sci 2019 Feb 12. Epub 2019 Feb 12.

Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Mailstop F-78, 4770 Buford Highway NE, Atlanta, GA, 30341, USA.

Background: Previous reports suggest that adults with inflammatory bowel disease (IBD) receive suboptimal preventive care.

Aims: The population-based study compared the receipt of these services by US adults with and without IBD.

Methods: Adults aged ≥ 18 years with IBD (1. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10620-019-05494-w
Publisher Site
http://dx.doi.org/10.1007/s10620-019-05494-wDOI Listing
February 2019
2 Reads